Global Flow Cytometry Market Report (2022 to 2031) - Featuring Beckman Coulter, Agilent Technologies and Danaher Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Flow Cytometry Global Market Report 2022, By Type, By Technology, By End User, By Application" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global flow cytometry market.

The global flow cytometry market is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.07 billion in 2025 at a CAGR of 7.6%.

Companies Mentioned

• Beckman Coulter
• Agilent Technologies
• Bio-Rad Laboratories
• Thermo Fisher
• Luminex
• Miltenyi Biotec
• Becton Dickinson and Company
• Sysmex
• Merck KGAA
• Danaher Corporation
• Apogee
• Stratedigm
• General Electric Company
• EMD Millipore
• Affymetrix
• Biomerieux S.A.
• Cytonome St.
• Enzo Life Sciences
• Enzo Biochem
• Sony Biotechnology
• Sysmex Partec
• Life Technologies
• BD
• ACEA BIO
• TAKARA BIO

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The flow cytometry market consists of sales of flow cytometry instruments, software and chemicals and related services. Flow cytometry is used to analyze characteristics of a biological cell such as cell size, cell count and cell complexity using laser optics. In the flow cytometry technique, cells are added to a fluid medium which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it to data displayed on a monitor.

The main types of flow cytometry are instruments, reagents and consumables, software, accessories, and services. Flow cytometry services include experimental design, specimen processing, acquisition and data analysis to support researchers, biotech and pharmaceutical companies in the process of drug development. The various technologies involved are cell-based, bead-based that are used in oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, and hematology. The different end-users include hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, and other end users.

The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. Flow cytometry uses light scattering to determine the identity of cells. These cells are given certain markers called CDs (clusters of differentiation), based on the type of scattering. For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing.

The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting "problem cells" in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry. In ELISA, colour changes in reagents are used to detect problematic cells. While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells. Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate. However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput.

High-throughput flow cytometry is an emerging trend in the flow cytometry market. This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique. Traditional cytometry methods are very slow, especially when several cells need to be tested within a day. Using high-throughput flow cytometry methods such as fluorescence-activated cell-sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time. Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis.

For more information about this report visit https://www.researchandmarkets.com/r/2pdg7j

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900